Obesity; Impaired Glucose Regulation; Prediabetes; Type 2 Diabetes MellitusTRE-SFR-EXNCT07726615
Time-Restricted Eating and Staple Food Reduction Combined With App-Supported Exercise for Weight and Glycemic Control
A study testing App-Supported Exercise Intervention, Staple Food Reduction and Early Time-Restricted Eating in people with Obesity; Impaired Glucose Regulation; Prediabetes; Type 2 Diabetes Mellitus, run by Peking University.
Trial summary
This multicenter, three-arm randomized controlled trial will evaluate the effects of early time-restricted eating and staple food reduction, each combined with an app-supported exercise intervention, on body weight and glycemic control among adults with obesity and abnormal glucose metabolism. Read more about this study
- Who is it for?
- Ages 18 to 50 years
- Conditions the study is for
- Obesity; Impaired Glucose Regulation; Prediabetes; Type 2 Diabetes Mellitus
- What is being tested?
- App-Supported Exercise Intervention, Staple Food Reduction and Early Time-Restricted Eating
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 300 participants
- Where
- No sites listed yet
- Study dates
- Jul 2026to Apr 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Age 18 to 50 years, all sexes.
- Body mass index (BMI) >=28 kg/m2.
- Willing and able to comply with study procedures and provide written informed consent.
- Resident living near a participating study site and able to complete scheduled visits.
- No habitual time-restricted eating or other fasting regimen, such as alternate-day fasting or fasting-mimicking diet.
- Abnormal glucose metabolism or diabetes, defined as fasting plasma glucose >5.6 mmol/L or HbA1c >5.7%.
Who cannot join
- Secondary obesity, such as hypothyroidism or Cushing syndrome.
- Use of weight-loss medication within 90 days before screening, or body weight change >5 kg within 90 days before screening.
- Pregnant, lactating, or planning pregnancy during the study period.
- Severe cardiac, hepatic, or renal dysfunction.
- Severe psychiatric disease or cognitive impairment that prevents cooperation with the study.
- Contraindication to exercise, such as severe osteoarthritis.
Show all 10Show fewer
- Unable or unwilling to follow the study diet and exercise intervention.
- Long-term use of medications that may significantly affect body weight.
- Active malignancy in any organ system.
- Any other condition that, in the investigator's judgment, may affect efficacy or safety evaluation or make the participant unsuitable for the study.
About this study
Official title: A Multicenter Randomized Controlled Trial of Time-Restricted Eating, Staple Food Reduction, and App-Supported Exercise for Weight Loss and Glycemic Improvement in Adults With Obesity and Abnormal Glucose Metabolism
This multicenter, three-arm randomized controlled trial will evaluate the effects of early time-restricted eating and staple food reduction, each combined with an app-supported exercise intervention, on body weight and glycemic control among adults with obesity and abnormal glucose metabolism. A total of 300 participants aged 18 to 50 years with BMI >=28 kg/m2 and impaired glucose regulation or diabetes will be enrolled at five centers in China and randomized 1:1:1 to app-supported exercise alone, staple food reduction plus app-supported exercise, or early time-restricted eating plus app-supported exercise. The intervention lasts 12 weeks, followed by a 12-week post-intervention follow-up.
Read the detailed description
All groups will use the Xiangdong Health app for exercise prescriptions, self-monitoring, and behavioral feedback. The staple food reduction group will reduce staple food intake by approximately one half at three meals without restriction of eating time. The early time-restricted eating group will consume food only between 07:00 and 15:00, with water allowed outside the eating window, without prescribed restriction of total daily energy intake. Outcomes will be measured at baseline, week 12, and week 24, including body weight, glycemic indices, continuous glucose monitoring metrics, body composition, blood pressure, blood biochemistry, urine tests, stool microbiome, dietary recall, physical activity, sleep, appetite, psychological measures, adherence, and adverse events.
- Being tested
- App-Supported Exercise Intervention, Staple Food Reduction, Early Time-Restricted Eating
- Keywords
- time-restricted eating; staple food reduction; app-supported exercise; obesity; abnormal glucose metabolism; continuous glucose monitoring
- Medical subject headings
- Obesity, Prediabetic State, Diabetes Mellitus, Type 2, Intermittent Fasting
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
App-Supported Exercise InterventionBehavioural
Participants receive individualized exercise prescriptions, self-monitoring, and behavioral feedback through the Xiangdong Health app for 12 weeks. The exercise program includes progressive aerobic exercise, resistance training, flexibility training, and balance training.
Staple Food ReductionBehavioural
Participants reduce staple food intake by approximately one half at three meals without restriction of eating time. This dietary strategy is combined with the same app-supported exercise intervention.
Early Time-Restricted EatingBehavioural
Participants consume food only from 07:00 to 15:00 each day, with water allowed outside the eating window. Total daily energy intake is not prescribed, and participants are advised to follow the Chinese Dietary Guidelines. This dietary strategy is combined with the same app-supported exercise intervention.
| Study group | Role | What they receive |
|---|---|---|
| App-Supported Exercise | Active comparator | Participants receive exercise prescriptions, self-monitoring, and behavioral feedback through the Xiangdong Health app for 12 weeks. The program includes progressive aerobic exercise, resistance training, flexibility training, and balance training. Receives: Behavioral: App-Supported Exercise Intervention |
| Staple Food Reduction Plus App-Supported Exercise | Experimental | Participants reduce staple food intake by approximately one half at three meals without restriction of eating time and receive the same app-supported exercise intervention for 12 weeks. Receives: Behavioral: App-Supported Exercise Intervention; Behavioral: Staple Food Reduction |
| Early Time-Restricted Eating Plus App-Supported Exercise | Experimental | Participants consume food only from 07:00 to 15:00 each day, with water allowed outside the eating window, without prescribed restriction of total daily energy intake, and receive the same app-supported exercise intervention for 12 weeks. Receives: Behavioral: App-Supported Exercise Intervention; Behavioral: Early Time-Restricted Eating |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in body weight from baseline to week 12
Body weight will be measured using a calibrated scale. The primary analysis will compare absolute change in body weight from baseline to week 12 among the three randomized groups.
Measured: Baseline and week 12
Change in CGM-derived glucose exposure and time in range from baseline to week 12
Continuous glucose monitoring (CGM) metrics will include glucose area under the curve and time in range (TIR), defined as the percentage of valid CGM readings between 3.9 and 10.0 mmol/L. Changes from baseline to week 12 will be compared among the three randomized groups.
Measured: Baseline and week 12
Secondary outcomes (28)
Change in BMI from baseline to week 12 and week 24
Calculated as weight in kg divided by height in meters squared (kg/m²). Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in body fat mass from baseline to week 12 and week 24
Change in body fat mass (measured in kilograms, kg) from baseline to week 12 and week 24, assessed by bioelectrical impedance analysis.
Measured: Baseline, week 12, and week 24
Change in fasting plasma glucose from baseline to week 12 and week 24
Fasting plasma glucose will be measured in millimoles per liter (mmol/L). Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in systolic blood pressure from baseline to week 12 and week 24
Systolic blood pressure will be measured in millimeters of mercury (mmHg). Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in CGM-derived mean glucose from baseline to week 12 and week 24
Mean glucose will be calculated from valid CGM readings and reported in millimoles per liter (mmol/L). Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in questionnaire-based behavioral and patient-reported measures from baseline to week 12 and week 24
Questionnaire-based measures include dietary intake, physical activity, sleep, psychological status, appetite, and intervention adherence.
Measured: Baseline, week 12, and week 24
Adverse events and serious adverse events
Adverse events and serious adverse events will be collected throughout the intervention and follow-up period and summarized by randomized group.
Measured: From baseline through week 24
Change in Waist circumference from baseline to week 12 and week 24
Measured in centimeters (cm). Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in Hip circumference from baseline to week 12 and week 24
Measured in centimeters (cm). Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in Waist-to-hip ratio (WHR) from baseline to week 12 and week 24
Calculated as a unitless ratio. Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in body fat percentage from baseline to week 12 and week 24
Change in body fat percentage (measured in %) from baseline to week 12 and week 24, assessed by bioelectrical impedance analysis.
Measured: Baseline, week 12, and week 24
Change in skeletal muscle mass from baseline to week 12 and week 24
Change in skeletal muscle mass (measured in kilograms, kg) from baseline to week 12 and week 24, assessed by bioelectrical impedance analysis.
Measured: Baseline, week 12, and week 24
Change in glycated hemoglobin (HbA1c) from baseline to week 12 and week 24
Glycated hemoglobin (HbA1c) will be measured as a percentage. Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in fasting plasma insulin from baseline to week 12 and week 24
Fasting plasma insulin will be measured in microunits per milliliter (µIU/mL). Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in homeostatic model assessment of insulin resistance from baseline to week 12 and week 24
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) will be calculated from fasting plasma glucose and fasting plasma insulin and reported as a unitless index. Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in diastolic blood pressure from baseline to week 12 and week 24
Diastolic blood pressure will be measured in millimeters of mercury (mmHg). Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in heart rate from baseline to week 12 and week 24
Heart rate will be measured in beats per minute (bpm). Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in total cholesterol from baseline to week 12 and week 24
Fasting serum total cholesterol will be measured in millimoles per liter (mmol/L). Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in triglycerides from baseline to week 12 and week 24
Fasting serum triglycerides will be measured in millimoles per liter (mmol/L). Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in low-density lipoprotein cholesterol from baseline to week 12 and week 24
Fasting serum low-density lipoprotein cholesterol (LDL-C) will be measured in millimoles per liter (mmol/L). Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in high-density lipoprotein cholesterol from baseline to week 12 and week 24
Fasting serum high-density lipoprotein cholesterol (HDL-C) will be measured in millimoles per liter (mmol/L). Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in alanine aminotransferase from baseline to week 12 and week 24
Serum alanine aminotransferase (ALT) will be measured in units per liter (U/L). Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in aspartate aminotransferase from baseline to week 12 and week 24
Serum aspartate aminotransferase (AST) will be measured in units per liter (U/L). Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in serum creatinine from baseline to week 12 and week 24
Serum creatinine will be measured in micromoles per liter (µmol/L). Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in serum uric acid from baseline to week 12 and week 24
Serum uric acid will be measured in micromoles per liter (µmol/L). Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in CGM-derived time above range from baseline to week 12 and week 24
Time above range (TAR) will be calculated as the percentage of valid CGM readings above 10.0 mmol/L. Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in CGM-derived time below range from baseline to week 12 and week 24
Time below range (TBR) will be calculated as the percentage of valid CGM readings below 3.9 mmol/L. Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Change in CGM-derived glucose coefficient of variation from baseline to week 12 and week 24
The glucose coefficient of variation (CV) will be calculated from valid CGM readings and reported as a percentage. Changes will be compared among the three randomized groups.
Measured: Baseline, week 12, and week 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2026
- Study startJul 2026 (estimated)
- Primary completionDec 2026 (estimated)
- Study completionApr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obesity; Impaired Glucose Regulation; Prediabetes; Type 2 Diabetes MellitusStudies of the same condition, open and under way.
- More trials run by Peking UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomized in a 1:1:1 ratio using a computer-generated sequence, stratified by study center, with allocation concealment using sequentially numbered opaque sealed envelopes or a central randomization process.
- Masking
- None (open label)
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Peking University
- Sponsor type
- University, hospital or other
- Collaborators
- Chinese PLA General Hospital, Beijing Pinggu District Hospital, Dongying Traditional Chinese Medicine Hospital, Ningbo Beilun Community Health Service Center, Qingdao Municipal Hospital
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07726615
- Sponsor's protocol ID
- IRB00001052-26093
- Acronym
- TRE-SFR-EX
- Status last verified
- Jul 2026
- First submitted
- 13 Jul 2026
- Last updated
- 24 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared publicly because the study includes sensitive health information and biological sample data. De-identified aggregate results will be reported in scientific publications.
Study at a glance
From the registry record, last updated by the sponsor on 24 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter Randomized Controlled Trial of Time-Restricted Eating, Staple Food Reduction, and App-Supported Exercise for Weight Loss and Glycemic Improvement in Adults With Obesity and Abnormal Glucose Metabolism
- ClinicalTrials.gov ID
- NCT07726615
- Acronym / sponsor ID
- TRE-SFR-EX / IRB00001052-26093
- Keywords
- time-restricted eating; staple food reduction; app-supported exercise; obesity; abnormal glucose metabolism; continuous glucose monitoring
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Peking UniversityUniversity, hospital or other
- Collaborators
- Chinese PLA General Hospital, Beijing Pinggu District Hospital, Dongying Traditional Chinese Medicine Hospital, Ningbo Beilun Community Health Service Center, Qingdao Municipal Hospital
- Study start
- Jul 2026 (estimated)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Apr 2027 (estimated)
- First posted
- 24 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This multicenter, three-arm randomized controlled trial will evaluate the effects of early time-restricted eating and staple food reduction, each combined with an app-supported exercise intervention, on body weight and glycemic control among adults with obesity and abnormal glucose metabolism. A total of 300 participants aged 18 to 50 years with BMI >=28 kg/m2 and impaired glucose regulation or diabetes will be enrolled at five centers in China and randomized 1:1:1 to app-supported exercise alone, staple food reduction plus app-supported exercise, or early time-restricted eating plus app-supported exercise. The intervention lasts 12 weeks, followed by a 12-week post-intervention follow-up.
Detailed description
All groups will use the Xiangdong Health app for exercise prescriptions, self-monitoring, and behavioral feedback. The staple food reduction group will reduce staple food intake by approximately one half at three meals without restriction of eating time. The early time-restricted eating group will consume food only between 07:00 and 15:00, with water allowed outside the eating window, without prescribed restriction of total daily energy intake. Outcomes will be measured at baseline, week 12, and week 24, including body weight, glycemic indices, continuous glucose monitoring metrics, body composition, blood pressure, blood biochemistry, urine tests, stool microbiome, dietary recall, physical activity, sleep, appetite, psychological measures, adherence, and adverse events.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- Participants will be randomized in a 1:1:1 ratio using a computer-generated sequence, stratified by study center, with allocation concealment using sequentially numbered opaque sealed envelopes or a central randomization process.
| Arm | Type | Receives |
|---|---|---|
| App-Supported Exercise | Active comparator | Behavioral: App-Supported Exercise InterventionParticipants receive exercise prescriptions, self-monitoring, and behavioral feedback through the Xiangdong Health app for 12 weeks. The program includes progressive aerobic exercise, resistance training, flexibility training, and balance training. |
| Staple Food Reduction Plus App-Supported Exercise | Experimental | Behavioral: App-Supported Exercise Intervention, Behavioral: Staple Food ReductionParticipants reduce staple food intake by approximately one half at three meals without restriction of eating time and receive the same app-supported exercise intervention for 12 weeks. |
| Early Time-Restricted Eating Plus App-Supported Exercise | Experimental | Behavioral: App-Supported Exercise Intervention, Behavioral: Early Time-Restricted EatingParticipants consume food only from 07:00 to 15:00 each day, with water allowed outside the eating window, without prescribed restriction of total daily energy intake, and receive the same app-supported exercise intervention for 12 weeks. |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Age 18 to 50 years, all sexes.
- Body mass index (BMI) >=28 kg/m2.
- Willing and able to comply with study procedures and provide written informed consent.
- Resident living near a participating study site and able to complete scheduled visits.
- No habitual time-restricted eating or other fasting regimen, such as alternate-day fasting or fasting-mimicking diet.
Key exclusion criteria (10 listed)
- Secondary obesity, such as hypothyroidism or Cushing syndrome.
- Use of weight-loss medication within 90 days before screening, or body weight change >5 kg within 90 days before screening.
- Pregnant, lactating, or planning pregnancy during the study period.
- Severe cardiac, hepatic, or renal dysfunction.
- Severe psychiatric disease or cognitive impairment that prevents cooperation with the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| App-Supported Exercise InterventionParticipants receive individualized exercise prescriptions, self-monitoring, and behavioral feedback through the Xiangdong Health app for 12 weeks. The exercise program includes progressive aerobic exercise, resistance training, flexibility training, and balance training. | Behavioural | App-Supported Exercise, Early Time-Restricted Eating Plus App-Supported Exercise, Staple Food Reduction Plus App-Supported Exercise |
| Staple Food ReductionParticipants reduce staple food intake by approximately one half at three meals without restriction of eating time. This dietary strategy is combined with the same app-supported exercise intervention. | Behavioural | Staple Food Reduction Plus App-Supported Exercise |
| Early Time-Restricted EatingParticipants consume food only from 07:00 to 15:00 each day, with water allowed outside the eating window. Total daily energy intake is not prescribed, and participants are advised to follow the Chinese Dietary Guidelines. This dietary strategy is combined with the same app-supported exercise intervention. | Behavioural | Early Time-Restricted Eating Plus App-Supported Exercise |
Primary outcome
Change in body weight from baseline to week 12
Time frame: Baseline and week 12
Body weight will be measured using a calibrated scale. The primary analysis will compare absolute change in body weight from baseline to week 12 among the three randomized groups.
Change in CGM-derived glucose exposure and time in range from baseline to week 12
Time frame: Baseline and week 12
Continuous glucose monitoring (CGM) metrics will include glucose area under the curve and time in range (TIR), defined as the percentage of valid CGM readings between 3.9 and 10.0 mmol/L. Changes from baseline to week 12 will be compared among the three randomized groups.
28 secondary outcomes
Change in BMI from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in body fat mass from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in fasting plasma glucose from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in systolic blood pressure from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in CGM-derived mean glucose from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in questionnaire-based behavioral and patient-reported measures from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Adverse events and serious adverse events
Time frame: From baseline through week 24
Change in Waist circumference from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in Hip circumference from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in Waist-to-hip ratio (WHR) from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in body fat percentage from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in skeletal muscle mass from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in glycated hemoglobin (HbA1c) from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in fasting plasma insulin from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in homeostatic model assessment of insulin resistance from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in diastolic blood pressure from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in heart rate from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in total cholesterol from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in triglycerides from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in low-density lipoprotein cholesterol from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in high-density lipoprotein cholesterol from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in alanine aminotransferase from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in aspartate aminotransferase from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in serum creatinine from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in serum uric acid from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in CGM-derived time above range from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in CGM-derived time below range from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Change in CGM-derived glucose coefficient of variation from baseline to week 12 and week 24
Time frame: Baseline, week 12, and week 24
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jul 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared publicly because the study includes sensitive health information and biological sample data. De-identified aggregate results will be reported in scientific publications.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing App-Supported Exercise Intervention, Staple Food Reduction and Early Time-Restricted Eating in people with Obesity; Impaired Glucose Regulation; Prediabetes; Type 2 Diabetes Mellitus, run by Peking University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 24 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in body weight from baseline to week 12 (time frame: Baseline and week 12). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2026.